Drugmaker Mallinckrodt may renege on $1.7 billion opioid settlement

Mallinckrodt says it is considering its financial alternatives, including a second bankruptcy, and might not make a $200 million opioid payment later this week. (Whitney Curtis/AP)

The generic drugmaker Mallinckrodt says the company's board might not make a $200 million opioid settlement payment scheduled for later this week.

In a June 5 filing with the Securities and Exchange Commission, the financially troubled firm said it faces growing questions internally and from creditors about the payout, which is part of a $1.7 billion opioid deal reached as part of a bankruptcy deal last year.